Matthew P. DeLisa

This paper introduces PepRePs, a system using peptide-retargeted phosphatases to selectively manipulate protein phosphorylation, showing reduced phosphorylation and downstream effects on cellular processes.

This paper develops programmable protein degraders (uAbs) that selectively knock down pathogenic β-catenin in vitro and in vivo, reducing tumor cell survival and proliferation.

The paper profiles gut bacterial extracellular vesicles (bEVs) and links their cargo composition to host transcriptional responses across different cell types.

This paper develops lipid nanoparticles for intracellular antibody delivery, showing efficacy in inhibiting cytosolic targets in cancer and disease models.

The paper describes methods to make a membrane-bound glycosyltransferase water-soluble for easier study and application in synthetic glycobiology.

This paper presents a cell-free manufacturing platform for producing conjugate vaccines with high glycosylation efficiency and purity, validated through immunogenicity testing in mice.

This paper demonstrates scalable cell-free production of active T7 RNA polymerase with high purity and activity, suitable for decentralized biotherapeutic manufacturing.

This study enhances the affinity and cytotoxicity of an anti-polysialic acid antibody through rational design and directed evolution, resulting in more potent variants.

This paper develops multifunctional reagents for nanoscale imaging of glycans using expansion microscopy, validated in C. elegans and mammalian cells.

The paper identifies a single-subunit oligosaccharyltransferase from Desulfovibrio marinus that enables glycosylation of full-length IgG antibodies in E. coli.

This study develops a method to deliver proteins into cells using ionizable lipid nanoparticles by modifying protein surfaces with an anionic cloak, demonstrating efficacy in cancer cell killing and signaling inhibition.

This paper develops a cell-free platform combining CFPS and AlphaLISA to rapidly study and engineer PTM installing proteins for therapeutic applications.

The paper describes a method to isolate full-length IgG antibodies from combinatorial libraries in E. coli using a bifunctional antigen substrate for selection.

This study develops a low-cost recombinant glycoconjugate vaccine against ETEC O148 and O78 that provides immunogenicity and protection in mice.

This paper develops a low-cost, thermostable cell-free protein synthesis system for producing conjugate vaccines without refrigeration, achieving ~$0.50 per dose after 4 weeks at room temperature.

This paper develops a method to produce N-linked glycoproteins using ribosome display in cell-free extracts, enabling their functional and structural analysis.

This paper introduces a microfluidic platform for cell-free glycoprotein synthesis that separates synthesis, glycosylation, and purification steps to improve yield and control.

The paper evolves Escherichia coli Tat translocases to enhance protein secretion, finding three variants that significantly increase periplasmic protein export compared to wildtype and SecYEG.

This paper introduces a method to construct and analyze neoglycoproteins by systematically modifying glycosylation sites in proteins and assessing the effects of glycan addition.

This paper introduces AddVax, a method to decorate bacterial outer membrane vesicles with biotinylated antigens to create vaccines, showing strong immune responses in mice.

This paper describes the engineering of ubiquibodies (uAbs) that degrade all forms of endogenous ERK1/2 protein kinase in multiple cell lines.

The paper improves cell-free glycoprotein synthesis by characterizing and enriching native membrane vesicles in bacterial extracts to enhance membrane-bound functionality.

This paper develops a portable, freeze-dried system for producing conjugate vaccines at the point-of-care, showing higher antibody responses in mice compared to traditional methods.

The paper introduces a cell-free platform for assembling protein glycosylation pathways and demonstrates its use in creating vaccine proteins and antibody constant regions with specific glycan motifs.

This study uses metabolic modeling to design E. coli strains that overproduce glycan precursors for glycoprotein production.

This paper discusses bacterial glycoengineering as a method to produce customized glycomolecules using recombinant expression of carbohydrate biosynthesis pathways.

This paper presents a cell-free platform for synthesizing active oligosaccharyltransferases (OSTs) and demonstrates its ability to produce and test multiple OSTs for glycosylation reactions.

The paper describes a pipeline for studying and engineering single-subunit oligosaccharyltransferases (ssOSTs) using in vivo and in vitro methods.